Biotechnology News

Phase 2 CLOVER study enrolled 66 patients across seven sites in metastatic colorectal cancerUpdated data show universal CCR5 expression, early ctDNA reductions and favorable tolerability VANCOUVER,...

Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Closing of...

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis has received a major shareholder notification from BlackRock, Inc. regarding its holdings in Novonesis. As of October 21, 2026,...

Encouraging first clinical data for Novastra Therapeutics’ novel XIRT™/OAP cancer immune therapy reported at ESMO Congress 2026

CARSON CITY, Nev., Oct. 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and...

SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics...

RADNOR, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third...

Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world’s largest gathering of pain professionals Growing body of data supports...

Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026

PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and...